BioLineRX Ltd

BLRX XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

15M

Short interest (May 15)

3.2%

Net Short (Jun 03 ): -0.1%

Borrow Fee

47.11%

↑ 29.7%

Available Shares

80K

↑ 37.1%

Price Chart

Company Overview

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Company Info

Exchange: NASDAQ

CIK: 0001498403

Asset Type: ADRC

Market Data

Market Cap: $14,751,100

Employees: 24

Status: Active

Short Interest

Current Borrow Fee 47.11%

Range: 47.11% - 56.78%

Available Shares 80K

Range: 20K - 80K

Recent Changes

Fee Change: ↑ 1.1%

Available Change: ↓ 5.9%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime